Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Inclusion Criteria: * diagnosis of primary nonbullous or bullous impetigo * affected area comprising 1 to 100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. * target area has total SIRS score of at least 3, including pus/exudate of at least 1 * normally active and otherwise in good health by medical history and physical examination Exclusion Criteria: * has a pre-existing skin condition or skin trauma with clinical evidence of secondary infection * has an infection that could not be appropriately treated with a topical antibiotic or severe manifestation of impetigo warranting systemic therapy * clinically significant mental illness * pregnant or breast-feeding * recent history, or strong potential for, alcohol or substance abuse. * skin condition that may interfere with the placement of study treatment or impede clinical evaluations * receipt of systemic drugs that affect the immune system within the past 3 months * receipt of any topical medication on the regions to be treated or topical antibiotics used for nasal decolonization within the past 24 hours